Clinical Trials


T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs

This study has been completed
Hoffmann-La Roche


Information provided by (Responsible Party)
NIH AIDS Clinical Trials Information Service Identifier

First received: July 21, 2001
Last updated: June 23, 2005
Last Verified: May 2002
History of Changes


The purpose of this study is to show if a dose of T-20 added to an anti-HIV combination (chosen specifically for each patient) lowers viral load by at least a certain level after 24 weeks as compared to an anti-HIV combination (chosen specifically for each patient) alone. Another purpose is to show if the patient response to T-20 will be maintained for 48 weeks.

Condition Intervention Phase
HIV Infections

Drug : Enfuvirtide
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Official Title: A Phase III Open-Label, Randomized, Active-Controlled Study Assessing the Efficacy and Safety of T-20 (HIV-1 Fusion Inhibitor) in Combination With an Optimized Background Regimen, Versus Optimized Background Regimen Alone, in Patients With Prior Experience and/or Prior Documented Resistance to Each of the Three Classes of Approved Antiretrovirals (Nucleoside Reverse Transcriptase, Non-Nucleoside Reverse Transcriptase and Protease Inhibitors)

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Enrollment: 525

Detailed Description:

An OB regimen is selected to be initiated at baseline by the physician and patient. The OB regimen is based on the patient's prior treatment history as well as the results from the first screening visit HIV-1 genotypic and phenotypic (GT and PT) resistance testing and prior GT/PT antiretroviral resistance testing (if available). Prior or current laboratory abnormalities, including triglycerides and cholesterol, should also be taken into account when selecting the OB regimen. Patients are stratified with respect to the following: 1) screening viral load (less than 40,000 or 40,000 or more copies/ml); and 2) number of allowed investigational antiretrovirals (0, 1, or 2). Patients then are randomized to receive 1 of the following treatments for 48 weeks: OB regimen or OB plus T-20 regimen. Patients are seen for evaluation of efficacy and safety at Weeks 1, 2, and 4, every 4 weeks through Week 24, and then every 8 weeks through Week 48. In addition, efficacy only is evaluated at Weeks 6, 10, and 14. Patients also may be seen at additional visits during the study for plasma HIV-1 RNA measurements to potentially confirm virological failure.
Patients initially randomized to the OB arm who meet the criteria for virological failure and who switch to OB plus T-20 after Week 8 are followed under a new ("switch") schedule of assessments. Patients are encouraged to change their OB regimen at the time of switch.
Patients initially randomized to the OB plus T-20 arm who meet the criteria for virological failure may continue to receive OB plus T-20 if the patient and the physician feel that there is sufficient benefit. Patients are encouraged to change their OB regimen after Week 8 if they choose to continue on OB plus T-20 despite meeting the criteria for virological failure.
Patients on OB or OB plus T-20 arm who meet the criteria for virological failure but who do not wish to either switch to T-20 (for patients initially randomized to OB arm) or continue with T-20 (for patients initially randomized to OB plus T-20) are allowed to remain in the study for a maximum of 1 month.
At the end of the 48 weeks of treatment, patients are allowed to participate in 1 of the following treatment extensions: a) roll-over and receive OB plus T-20 (for patients receiving OB alone); or b) continue taking OB plus T-20 (for patients already receiving OB plus T-20), for a maximum of an additional 48 weeks (plus 4 weeks safety follow-up period), or until 12 weeks after commercial availability of T-20 in the country in which they are treated, whichever comes first. All patients are followed for a maximum of 100 weeks from their initial baseline visit date.



Ages Eligible for Study: 16 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  


Inclusion Criteria
Patients may be eligible for this study if they:

  • Are HIV infected.
  • Are at least 16 years of age.
  • Have an HIV-1 RNA of at least 5,000 copies/ml.
  • Have received anti-HIV drugs for at least 3 months and/or have written records of
resistance to at least 1 member of each of the 3 classes of anti-HIV drugs (nucleoside reverse transcriptase inhibitors [NRTIs], nonnucleoside reverse transcriptase inhibitors [NNRTIs], and protease inhibitors [PIs]). Resistance to NNRTIs may not be required in certain cases.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00021554


Carlton Clinic
Carlton, Australia
Holdsworth House General Practice
Darlinghurst, Australia
Saint Vincent's Hosp
Darlinghurst, Australia
Royal Brisbane Hosp
Herston, Australia
Alfred Hosp
Prahan, Australia
Prahran Market Clinic
South Yarra, Australia
Taylors Square Clinic
Sydney, Australia
Inst of Tropical Medicine
Antwerpe, Belgium
CHU Saint Pierre
Brussels, Belgium
UZ Gasthuisberg
Leuven, Belgium
Rheinische Friedrich Wilhelms Universitaet Medizinische
Bonn, Germany
Klinikum Der Johann Wolfgang Goethe Universitat
Frankfurt, Germany
Allgemeines Krankenhaus St Georg
Hamburg, Germany
Universitatskrankenhaus Eppendorf
Hamburg, Germany
UO Malattie Infettive
Firenze, Italy
Clinica Malattie Infettive
Milano, Italy
Ospedale Amedeo di Savoia
Torino, Italy
Natac Med Centre
Amsterdam, Netherlands
Univ Medical Center Utrecht
CX Utrecht, Netherlands
Hospital Germans Trias I Pujol
Barcelona, Spain
Hosp La Paz
Madrid, Spain
Hospital General Universitario
Valencia, Spain
University Hospital Mas
Malmoe, Sweden
Karolinska Hospital
Stockholm, Sweden
Venhalsan Soder Hosp
Stockholm, Sweden
Univ Hosp Basel / Med Outpatient Dept
Basel, Switzerland
Hopital cantonal / Div des maladies infectieuses
Geneve, Switzerland
Lausanne, Switzerland
Universitatsspital Zurich
Zurich, Switzerland
United Kingdom
Brighton Gen Hosp
Brighton, United Kingdom
Western Gen Hosp
Edinburgh, United Kingdom
Royal Liverpool Univ Hosp
Liverpool, United Kingdom
Chelsea and Westminster Hosp
London, United Kingdom
King's College Hospital
London, United Kingdom
Royal Free Hosp
London, United Kingdom
Univ College London Med School
London, United Kingdom
North Manchester Gen Hosp
Manchester, United Kingdom

Sponsors and Collaborators

Hoffmann-La Roche
More Information

More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT00021554   History of Changes  
Other Study ID Numbers: 295D  
Study First Received: July 21, 2001  
Last Updated: June 23, 2005  

Keywords provided by NIH AIDS Clinical Trials Information Service:

Drug Therapy, Combination
HIV Protease Inhibitors
RNA, Viral
Reverse Transcriptase Inhibitors
Anti-HIV Agents
Viral Load

Additional relevant MeSH terms:
HIV Infections
Protease Inhibitors
HIV Protease Inhibitors
Enfuvirtide processed this data on July 20, 2018
This information is provided by